Azura Ophthalmics Expands Broad Intellectual Property Portfolio to 12 U.S. and European Patents
Press Release — Supports continued advancement of first-in-class Ophthalmic Keratolytics for ocular surface diseases — TEL AVIV, Israel & MELBOURNE, Australia, October 19, 2022 – Azura Ophthalmics Ltd., a clinical-stage biopharmaceutical company developing a new therapeutic class of Ophthalmic Keratolytics for ocular surface diseases, today announced the company’s U.S. 11,459,351 patent (the ‘351 patent) was […]